Ascendis Pharma A/S (ASND) - 14.58% Below 52-Week High: Buy or Wait?

Stock Details

Ascendis Pharma A/S (ASND), a prominent company in the healthcare sector within the biotechnology industry, is based in Denmark and primarily trades on the NMS.Currently, the stock is trading at $241.00. Over the past 52 weeks, it has ranged between $186.05 and $282.15. This places the current price at 85.4% of its 52-week high and 29.5% above its 52-week low. Recent trading volume was recorded at 43. The 14-day Relative Strength Index (RSI) stands at 36.30, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $256.75 by 6.13%. Similarly, it is above its 200-day moving average of $233.53 by 3.20%. The MACD histogram is -1.27, indicating bearish momentum (MACD Line: 1.42, Signal Line: 2.69).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

18.47

Near market average

Forward P/E

21.56

Earnings expected to decline

Price to Book

9.46

EV/EBITDA

58.40

EPS (TTM)

$12.98

Price to Sales

15.06

Q:How is ASND valued relative to its earnings and growth?

Ascendis Pharma A/S trades at a P/E ratio of 18.47, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 21.56 is higher than the current P/E, indicating analysts expect earnings to decline over the next year.

Q:What is ASND's risk profile compared to the market?

Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

70.84%

Operating Margin

64.98%

EBITDA

$263.45M

Return on Equity

118.78%

Return on Assets

9.58%

Revenue Growth (YoY)

114.70%

Q:How profitable and efficient is ASND's business model?

Ascendis Pharma A/S achieves a profit margin of 70.84%, meaning it retains $70.84 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 64.98% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 118.78% and ROA at 9.58%, the company generates strong returns on invested capital.

Q:What are ASND's recent growth trends?

Ascendis Pharma A/S's revenue grew by 114.70% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$15.8B

Revenue (TTM)

$1.05B

Revenue/Share (TTM)

$16.89

Shares Outstanding

65.78M

Book Value/Share

$25.36

Asset Type

EQUITY

Q:What is ASND's market capitalization and position?

Ascendis Pharma A/S has a market capitalization of $15.8B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 65.78M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does ASND's price compare to its book value?

Ascendis Pharma A/S's book value per share is $25.36, while the current stock price is $241.00, resulting in a price-to-book (P/B) ratio of 9.50. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$312.52

29.68% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for ASND?

16 analysts cover ASND with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $312.52 implies 29.7% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on ASND?

Current analyst recommendations:3 Strong Buy, 13 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 16, 2026, 02:19 AM

Technical Indicators

RSI (14-day)

36.30

Neutral

50-Day Moving Average

$256.75

-6.13% below MA-50

200-Day Moving Average

$233.53

3.20% above MA-200

MACD Line

1.42

MACD Signal

2.69

MACD Histogram

-1.27

Bearish

Q:What does ASND's RSI value tell investors?

The RSI (Relative Strength Index) for ASND is currently 36.30, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret ASND's MACD and moving average crossovers?

MACD analysis shows the MACD line at 1.42 below the signal line at 2.69, with histogram at -1.27. This bearish crossover indicates downward pressure. The wide histogram confirms strong momentum. The 50-day MA ($256.75) is above the 200-day MA ($233.53), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Sep 16, 2026, 12:57 AM

Ascendis Pharma A/S (ASND) Stock